Risankizumab-Rzaa

Common brands: Skyrizi, Vitamin D, Humira, Acid Reducer, Ecotrin

Top reporter: Abbvie Inc.

Interleukin-23 Antagonist [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Corticosteroid [EPC]Provitamin D2 Compound [EPC]Proton Pump Inhibitor [EPC]
76,587
Total Reports
71,946
Serious Reports
2,682
Death Reports
30
Reported Reactions
Death Report Ratio: Moderate (3.50%)

Patient Demographics

Male
31,557
Female
41,380

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Risankizumab-Rzaa.

# Reaction Reports % of Total
1 PSORIASIS 7,578
13.4%
2 DRUG INEFFECTIVE 3,382
6.0%
3 PAIN 3,019
5.3%
4 FATIGUE 2,890
5.1%
5 ARTHRALGIA 2,866
5.1%
6 PRURITUS 2,600
4.6%
7 COVID-19 2,234
3.9%
8 SURGERY 2,061
3.6%
9 DEATH 2,022
3.6%
10 FALL 2,003
3.5%
11 DEVICE ISSUE 1,913
3.4%
12 DIARRHOEA 1,828
3.2%
13 HEADACHE 1,796
3.2%
14 CROHN^S DISEASE 1,782
3.2%
15 RASH 1,414
2.5%
16 NAUSEA 1,363
2.4%
17 NASOPHARYNGITIS 1,308
2.3%
18 MALAISE 1,228
2.2%
19 THERAPEUTIC RESPONSE SHORTENED 1,226
2.2%
20 PNEUMONIA 1,223
2.2%
21 ABDOMINAL PAIN 1,208
2.1%
22 PAIN IN EXTREMITY 1,177
2.1%
23 CEREBROVASCULAR ACCIDENT 1,175
2.1%
24 ERYTHEMA 1,136
2.0%
25 INTESTINAL OBSTRUCTION 1,067
1.9%
26 DIZZINESS 1,065
1.9%
27 ILLNESS 1,057
1.9%
28 SKIN CANCER 1,001
1.8%
29 BACK PAIN 977
1.7%
30 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 961
1.7%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.